New 24-Valent vaccine aims to shield children from more pneumonia strains

NCT ID NCT07300644

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: Sinovac Life Sciences Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a new vaccine called PCV24 in 420 healthy children aged 2 months to 5 years. The vaccine targets 24 types of pneumococcal bacteria, which can cause pneumonia, meningitis, and ear infections. Researchers will compare it to an existing vaccine to see if it is safe and triggers a strong immune response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 24-valent pneumococcal conjugate vaccine (PCV24)
What this could lead to: If successful, this vaccine could protect children against 24 types of pneumococcal bacteria, potentially preventing more infections than current vaccines.
What could go wrong: This is an early phase 2 trial with only 420 children, so results may not apply to all kids. The vaccine may not work as well as expected or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL INFECTIOUS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pneumococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PNEUMOCOCCAL INFECTIOUS DISEASE

Contacts and locations

Locations

Qichun District Center for Disease Prevention and Control
RECRUITING

Huanggang, Hubei, China
Xian'an District Center for Disease Prevention and Control
RECRUITING

Xianning, Hubei, China
Xiangzhou District Center for Disease Prevention and Control
RECRUITING

Xiangyang, Hubei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.